Generic placeholder image

Current Drug Targets - Cardiovascular & Hematological Disorders

Editor-in-Chief

ISSN (Print): 1568-0061
ISSN (Online): 1568-0061

Drug Therapy in Brugada Syndrome

Author(s): Manlio F. Marquez, Gabriel Salica, Antonio G. Hermosillo, Gustavo Pastelin and ">Manuel Cardenas

Volume 5 , Issue 5 , 2005

Page: [409 - 417] Pages: 9

DOI: 10.2174/156800605774370353

Price: $65

Abstract

Sudden cardiac death in healthy individuals with structurally normal hearts and a characteristic morphology of the QRS complex resembling a right bundle branch block with elevation of the ST segment in V1 to V3 is known as Brugada syndrome (BrS). Although placement of an implantable cardioverter-defibrillator is considered the only effective therapy for symptomatic patients, some authors have repeatedly reported a beneficial effect of quinidine and isoproterenol in patients with BrS. Also, isolated case reports on the usefulness of cilostazol, sotalol, and mexiletine have been described. The present article reviews the mechanisms by which these drugs may act and their role in the pharmacotherapy of BrS. Other possible agents, mainly Ito blockers, are also reviewed.

Keywords: brugada syndrome, sudden cardiac death, ventricular fibrillation, arrhythmic storm, quinidine, isoproterenol, cilostazol, sotalol, mexiletine, tedisamil


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy